Neurology Central

Gene-editing technology allows scientists to measure alpha-synuclein levels

Researchers from the University of Central Florida (FL, USA) are using CRISPR gene-editing technology to develop a novel screening tool for Parkinson’s disease. Their findings demonstrate how the research team could “light up” and monitor the brain protein alpha-synuclein, which has been associated with this neurodegenerative disease. The study was published in Scientific Reports and could lead to new therapeutic strategies for Parkinson’s.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.